Campbell Rogers is leaving his post as chief scientific officer for Johnson & Johnson’s (NYSE:JNJ) Cordis Corp. – a role created for him in July 2006 – to take the chief medical officer job at startup HeartFlow.
Delcath Systems Inc.
Ortho market growth stable but low | Wall Street Beat
The market for hip and knee implants is stable but mired in a low-growth stage, according to analysts who attended the American Academy of Orthopedic Surgeons conference in San Francisco last week.
Although the abrupt departure of Stryker CEO Steve MacMillan drew the lion’s share of attention at the AAOS event, analysts from Barclays Capital and Leerink Swann agreed that the sector’s outlook calls for low-single-digit growth.
Becton Dickinson lands clearance for 10-minute flu test | Regulatory Roundup
Becton Dickinson & Co. (NYSE:BDX) won FDA 510(k) clearance for its BD Veritor 10-minute diagnostic test for influenza A and B last month, amid rumors that the Franklin Lakes, N.J.-based company is ripe for buyout.
Veritor is the first rapid flu test with a digital readout, while older tests are slower, less accurate and more difficult to interpret, according to BD.
SonoSite taps new CFO | Personnel Moves
SonoSite (NSDQ: SONO) said it’s replacing retiring CFO Marcus Smith with Anil Amlani, head of its VisualSonics subsidiary.
Smith’s last day as the ultrasound device maker’s top financial mind is today; he’s slated to stay on at the Bothell, Wash.-based company until Jan. 5, according to a press release.
Smith had been with SonoSite since 2007, according to the release.
Delcath, Systagenix, TRIGOcare and Bio-Reference Laboratories tout new deals
Delcath Systems’ (NSDQ:DCTH) agreement with the European Institute of Oncology will launch European commercialization for the New York-based company’s Chemostat organ-targeting chemotherapy system.
Under the terms of the deal, Delcath will provide the Milan, Italy-based cancer center with logistics and clinical training support for the Chemostat system, which is awaiting full CE Mark approval.
CareFusion’s bottom line up 76 percent | Earnings Roundup
CareFusion Corp.’s (NYSE:CFN) first-quarter profits are up 76 percent from 2011 numbers for the three months ended Sept. 30, in spite of a recall of its Avea ventilators.
CareFusion posted profits of $67 million, or 30 cents per share, on a sales of $844 million for the quarter – a top-line increase of 4.1 percent compared with $811 million during the same period last year. But Q1 2011 profits were only $38 million, or 17 cents per share.
Delcath’s ChemoSat goes another round with the FDA
Delcath Systems Inc.’s (NSDQ:DCTH) ChemoSat organ-targeting chemotherapy system will get a pre-new drug application meeting with the FDA mid-January 2012, the company announced this week.
The ChemoSat device uses a system of tubes to localize the delivery of toxic chemotherapy agents by isolating the targeted organ — in this case, the liver — from the rest of the body’s bloodstream.
Masimo lands clearance in U.S. and Europe | Regulatory Roundup
Masimo Corp. (NDSQ:MASI) landed clearance in the U.S. and Europe for its Radical-7 non-invasive pulse oximeter with rainbow acoustic monitoring technology.
The Irvine, Calif.-based company’s system provides doctors with continuous readings of acoustic respiration rate waveform and measurements.
Masimo added a new feature called In Vivo Adjustment, not yet approved by the FDA that allows doctors to account for individual patient biases and adjust the device to readings from invasive blood analysis devices.
Diabetes: Remote monitoring diabetes management system wins FDA clearance | Regulatory Roundup
ALR Technologies Inc. (OTC:ALRT) landed FDA clearance for its Health-e-Connect System for diabetes management programs.
The web-based patient management platform allows doctors to remote monitor diabetic patients, a system that could result in significant savings to the the U.S. health care system through enhanced adherence to care plans, according to ALRT.
Medical device investment rose during Q2, even as deal volume fell | Wall Street Beat
Medical device investment deals got fatter and less frequent during the second quarter, as the value of deals grew 9 percent but their number slid 17 percent, according to PricewaterhouseCoopers.
Backers pumped $841 million into med-tech firms with 90 deals during the three months ended June 30, according to the consulting firm’s MoneyTree report. That’s up 26 percent and 3 percent, respectively, over the first quarter. The industry’s share of the venture capital cash spend on life sciences last quarter ticked down to 40 percent, however, compared with Q1 numbers.
Ballantyne takes CFO post at Avedro | Personnel Moves
Waltham, Mass.-based medical device and pharmaceutical company Avedro appointed industry veteran C. Evan Ballantyne as its new chief financial officer.
Prior to the appointment, Ballantyne was the VP & CFO of biopharmaceutical company Clinical Data Inc., chief financial officer of Beverly, Mass.-based ZymeQuest, and vice president at chief operating officer at the ACNielsen Corporation.